Clinical Trial Update: forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

View source ↗

Summary

The FORXIGA prescription event monitoring program (PEMP) for dapagliflozin in type 2 diabetes has been terminated. This serves as a status update on a post-mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Status: TERMINATED